OncoBone Ventures Limited has changed its name to OncoBone Therapeutics Ltd. At the same time, the company moved to London and changed its accounting firm to London-based Haysmacintyre LLP.
OncoBone Therapeutics is also proud to announce receiving a significant bridge loan funding originating from government and bank sources in Finland.
Jussi Halleen, CEO of OncoBone Therapeutics says: “It has been frustrating to note the difficulty in fundraising in UK, and also globally in the current very challenging economic situation. Therefore, we are grateful for the Finnish government and bank sources for their understanding of the high potential of our unique business model.”
Tiina Kähkönen, CSO of OncoBone Therapeutics adds: “This funding package will be extremely important for our business, as it allows us to advance critically important preclinical efficacy studies that will hopefully attract further funding and out-licensing opportunities for our therapeutic assets.”
